5.44
+0.31
+(6.07%)
At close: April 17 at 4:00:00 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
57,675
57,675
84,513
75,743
68,791
Cost of Revenue
20,879
20,879
22,893
30,775
32,084
Gross Profit
36,796
36,796
61,620
44,968
36,707
Operating Expense
148,036
148,036
200,819
248,532
215,708
Operating Income
-111,240
-111,240
-139,199
-203,564
-179,001
Net Non Operating Interest Income Expense
-10,844
-10,844
-12,312
-12,244
-14,659
Other Income Expense
1,541
1,541
-2,122
2,344
29,307
Pretax Income
-120,543
-120,543
-153,633
-213,464
-164,353
Tax Provision
312
312
521
449
473
Net Income Common Stockholders
-55,890
-55,890
-68,669
-94,607
-64,703
Diluted NI Available to Com Stockholders
-55,890
-55,890
-68,669
-94,607
-64,703
Total Operating Income as Reported
-110,379
-110,379
-142,342
-203,564
-188,541
Total Expenses
168,915
168,915
223,712
279,307
247,792
Net Income from Continuing & Discontinued Operation
-45,997
-45,997
-60,637
-86,575
-64,703
Normalized Income
-46,173.17
-46,173.17
-61,648.99
-87,466.91
-94,010
Interest Income
2,683
2,683
3,003
1,398
649
Interest Expense
11,588
11,588
11,915
10,417
11,394
Net Interest Income
-10,844
-10,844
-12,312
-12,244
-14,659
EBIT
-108,955
-108,955
-141,718
-203,047
-152,959
EBITDA
-104,491
-104,491
-135,721
-193,694
-146,168
Reconciled Cost of Revenue
19,839
19,839
20,663
30,775
32,084
Reconciled Depreciation
4,464
4,464
5,997
9,353
6,791
Net Income from Continuing Operation Net Minority Interest
-45,997
-45,997
-60,637
-86,575
-64,703
Total Unusual Items Excluding Goodwill
223
223
1,281
1,129
29,307
Total Unusual Items
223
223
1,281
1,129
29,307
Normalized EBITDA
-104,714
-104,714
-137,002
-194,823
-175,475
Tax Rate for Calcs
0
0
0
0
--
Tax Effect of Unusual Items
46.83
46.83
269.01
237.09
--
12/31/2021 - 11/14/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CHM.AX Chimeric Therapeutics Limited
0.0050
0.00%
ALA.AX Arovella Therapeutics Limited
0.0780
0.00%
XOMAP XOMA Royalty Corporation
25.95
-0.54%
CYTOF Altamira Therapeutics Ltd.
0.0700
0.00%
FNCH Finch Therapeutics Group, Inc.
13.00
+0.39%
TBPH Theravance Biopharma, Inc.
8.62
+0.29%
DYAI Dyadic International, Inc.
1.2300
-0.81%
CALC CalciMedica, Inc.
1.5500
+0.65%
RADX Radiopharm Theranostics Limited
4.3000
-0.69%
NEUP Neuphoria Therapeutics Inc.
5.14
+0.38%